posted
not HOD but still a great close just have a feeling we get a PR tomorrow but really have nothing to base that on.Someone jumped over me on the last by at .056 but thats OK,this will be looking real good soon. I can see .08's as an easy target,just look at the share depth from .059 to .125,sure isn;t going to take much buying to bust the .08 and higher imo. This is a rock solid investment for a biotech play!
posted
johnny...right now I am slowly loading up on PMED and also already loaded with AMEP for the winter months.CLBE is by far the most undervalued of the lot right now and should be heading back to the high teens or low .20's where it normally trades and then much higher over the next 3 to 6 months. I think its clearly going to be another BIPH type move in the making.I am currently on vacation in Florida for Biketoberfest and have not done any real DD on anything worth talking about yet ut will finish up a few when I get back on the 24th or 25th.
posted
I do agree with you about CBLE and PMED. PMED should be remove from SHO list tomorrow...If si this stock will run. SYCI is a very good play too because still unknow from investor communauty...I like this king of stock before they tend to run fast after their discovery...
Scientists in separate experiments have obtained embryonic stem cells from mice without destroying an embryo. This could remove moral and ethical objections to using embryonic stem cells for medical research toward possible cures for Alzheimer's, diabetes, Parkinson's spinal injuries and other health problems. Embryonic stem cells are master cells that can develop into any part of the body: skin, bone, muscle, brain. However, when the cells are extracted, the embryo dies. Opponents of embryonic stem-cell research call it murder; President Bush has blocked federal money from supporting new lines of embryonic stem-cell research.
Scientists at the Massachusetts Institute of Technology were able to extract stem cells from eggs that were gene-blocked from developing into an embryo. Dr. William Hurlbut, a member of the President's Council of Bioethics, has endorsed this method because the eggs cannot produce an embryo that will develop.
A study at Advanced Cell Technology, a Worcester, Mass., company, adapted a fertility clinic technique of removing a single cell from an embryo. While clinics use the cell to test for genetic disorders, the company used it to establish a stem-cell line. In both instances, the embryo goes on to develop.
Another breakthrough of sorts occurred in August, when a Harvard University team of scientists were able to fuse an embryonic stem cell and an adult skin cell. The stem cell reprogrammed the adult cell to revert to a stem cell. If scientists can learn how the stem cell changed the adult cell, it may be possible to reprogram adult cells without using stem cells. That goal, those involved said, may be five to 10 years away.
Privately funded embryonic stem-cell research is being done here as well as overseas. Research in adult stem cells is also being conducted. Some scientists contend that embryonic stem cells have better potential for medical treatments than adult cells.
If science can extract those cells without destruction of the embryo, that potential could be realized without the moral and ethical doubts that now hinder research.
"I think scientists would be far better to concentrate on other areas of stem cell research such as amniotic and adult stem cells which show far more promise"
Stem-cell researchers debate ethics of new methods
BY JEREMY MANIER
Chicago Tribune
CHICAGO - (KRT) - When researcher Rudolf Jaenisch started work earlier this year on a method of producing embryonic stem cells that would avoid ethical objections, one of his first hurdles was not scientific but personal: He did not believe there was any moral problem in the first place.
But practical considerations led Jaenisch and his team at the Massachusetts Institute of Technology to attempt the new stem cell extraction method, which they described in the journal Nature this week.
The need to destroy embryos to obtain stem cells has aroused powerful opposition to federal funding of such work. But Jaenisch thought if he could extract the cells without destroying a viable embryo, it might satisfy the opponents. And less controversy could mean more money for the field.
"I don't really have the objections that many people do have," Jaenisch said. "But you realize the realities in this country ... I think we need a compromise in this debate."
Jaenisch's report is one of two new studies in Nature that outline ways of making embryonic stem cells without destroying a viable embryo. Jaenisch harvested stem cells from a mouse embryo that was not viable: It was genetically altered so it could not develop in the womb. A separate group at Massachusetts-based Advanced Cell Technology was able to take cells from a normal mouse embryo without destroying it.
Some ethicists believe the work could help quell the uproar over federal funding of stem cell research, though others say the new methods are no better ethically than the techniques that caused the original objections.
That even the researchers involved are ambivalent illustrates the keen difficulty of finding common ground on the issue. William Hurlbut, a Stanford University bioethicist who first proposed the method that Jaenisch used, said the researchers are sincere in seeking a solution, though he acknowledged the irony of the situation.
"This is a strange moment in science, because scientists are trying to solve a problem that they don't feel is a problem," Hurlbut said.
In fact, Jaenisch voiced skepticism about the ethical merits of Hurlbut's idea during an interview with the Chicago Tribune in May. At that moment, Jaenisch now says, his own team already was trying to make the technique work.
The process involves altering a method of stem cell extraction called nuclear transfer, or therapeutic cloning.
In the original technique, researchers make an embryo by placing the nucleus of an adult cell in an egg cell that has been emptied of DNA. After an electric jolt, the egg begins dividing like an embryo, eventually forming a ball of cells that contains stem cells. Such cells can form any kind of tissue, offering the potential of new treatments for conditions such as Parkinson's disease and diabetes.
Hurlbut proposed altering this technique so that the ball of cells, called a blastocyst, cannot form a full-fledged person. Jaenisch's team did that in mice by silencing a gene called cdx2, which helps form the embryo's outer wall and, eventually, the placenta that keeps a fetus alive.
Such deficiencies, applied to human cells, would result in an entity with "a dramatically different developmental potential than a human embryo," Hurlbut said. Skeptics contend it would still be an embryo, albeit a damaged one.
In May, when the President's Council on Bioethics issued a report that contained some praise and criticism of Hurlbut's technique, Jaenisch agreed with many of the critics.
"Does being human or not depend on the state of one particular gene? That doesn't make sense," Jaenisch said.
Jaenisch still doesn't agree with the moral basis of the new technique, he said. But he said it was an interesting experiment that could provide a practical foundation for advancing the field.
The method doesn't solve any moral problem for Richard Doerflinger, deputy director of pro-life activities for the U.S. Conference of Catholic Bishops. In an e-mail response to questions, Doerflinger said taking out the cdx2 gene "seems to make a very damaged human embryo that cannot survive past a few days of development (instead of making a new entity that is not an embryo)."
Like Jaenisch, Robert Lanza, leader of the research team at Advanced Cell Technology, has long argued that embryonic stem cell research is morally acceptable as is.
Still, he said, "I regard the embryo with respect. If we can do this without offending anyone, fine."
A new project has been launched to discover whether a patient's own stem cells can be used to treat heart disease.
The study, funded by the Heart Cells Foundation, is being undertaken at the Barts and The London NHS Trust, where researchers will conduct a four-year study examining 700 patients.
Experts will use three different types of stem cell therapy techniques on three randomised control groups – the first made up of patients whose hearts are failing due to a previous heart attack; a group of patients suffering from dilated cardiomyopathy; and a group made up of patients who had just suffered a heart attack.
Doctors will extract stem cells from bone marrow in some patients' hips to inject into their major coronary artery or into their heart in a minimally invasive operation, while other patients will receive growth factor drugs to encourage their stem cells to spill out into the blood stream.
Lead researcher Dr Anthony Mathur said: "This is one of the biggest and most comprehensive trials of its kind in the world.
"Our studies will tell us if adult stem cells in bone marrow can repair damaged hearts and if so how these cells should be administered to patients.
"There is growing evidence to suggest that stem cells may benefit people with serious heart conditions, such as heart failure or those who have had heart attacks."
The Heart Cells foundation was set up by Ian Rosenberg, who suffered from such severe heart disease he was given months to live, until he received stem cell therapy in Germany.
"Stem cell therapy has given me years I never thought I would have," he said.
"I set up the Heart Cells Foundation so that others may benefit from this new and exciting science."
posted
a lot of focus is being put into adult stem cell issues and CLBE is right in the midst of it among other things (gotta a feeling we will be getting news involving the companies DNA research soon,a completely differant division)
posted
looks like the MM's are going to get jiggy early.I would like to see an early dip but so far don't see it,got some freed up cash now to buy another small block.
posted
well people everyone have a great day! I am heading over to Daytona for a while and hopefully be back to see an ALL TIME HIGH! (LOL...hey I can wish right?)
posted
Good Morning all,I see we were slightly down yesterday but bid is strong in the low .05's now.Just thing where its going to be when they announce they are in the black and showing profit this year!!
posted
from the last 10-k,2 major points of interest that many keep forgetting about.
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
posted
the closer we get to the end of this month and into next I think CLBE and also AMEP both will get real active.Per the 10-k it clearly shows the direction they intend on taking this stock.It takes balls to include a statement in an SEC filing claiming "The company believes that it will report a net profit for 2005." and also "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."...these are bold statements imo.This stock is not going to continue trading within these ranges for much longer.
posted
johnny...I honestly beieve it will over time,this is why I am loading now at these levels when opportunity permits,even have a 5k buy in now for .051,I did the same with BIPH under a dime when no one wanted it...now look.I am in no hurry at all,this is a mid to long play (within 12 months from last August)
posted
LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets. The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services. "LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection. LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells.
About CalbaTech CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
posted
MACD crossing into the positive moving averages. Chart drawing out nice indicators. Positive convergences forming and staying close to 50 day moving average. Usually a nice breakout to a higher high awaits a chart forming an ascending MACD. Short term candles indicates that with a little support at these levels, we keep posibility of making new short term highs alive.
Holding nicely at these levels and the fundamentals of this company dont look decent for a penny stock. Company forecast puts out that numbers are only getting better as time progresses.
I like your picks Questsolver. You always post competent plays. Of course every penny stock involves risk, but yours seem to be risk managed. : )
Bright future awaits is. At these levels, getting filled on your orders brings a good feeling. Clever investors know what theyre holding on to. GLTA this week, and lets not forget, small term fluctuations can be deceiving.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
